NASDAQ · Biotechnology

BriaCell Therapeutics Corp. Warrant (BCTXZ) Stock

$0.10 +8.47% NASDAQ: BCTXZ Healthcare

BriaCell Therapeutics Corp., a biotechnology company based in West Vancouver, Canada, is intensely focused on immuno-oncology, dedicated to engineering novel immunotherapies for cancer treatment. Its flagship compound, Bria-IMT, is a whole-cell cancer vaccine presently in Phase I/IIa clinical development, where it's being evaluated in conjunction with the investigational immunotherapy retifanlimab.

Valuation

MetricValue
Price$0.10
Market Cap$188186
P/E Ratio-0.30
P/B Ratio1.11
P/S Ratio0.00
EPS (TTM)$-62.95
52-Week High$0.10
52-Week Low$0.09
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-147.92%
ROA-113.23%
ROCE-136.31%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio7.07

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-7.0M$-15.0M$-23.0M$-33.0M$-28.0M
Net Profit$-14.0M$-27.0M$-20.0M$-5.0M$-27.0M
EPS$-467.51$-259.50$-195.00$-43.68$-62.95
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$58.0M$43.0M$27.0M$6.0M$22.0M
Total Liabilities$30.0M$32.0M$31.0M$9.0M$4.0M
Cash$57.0M$41.0M$21.0M$1.0M$11.0M
Borrowings$0$0$0$0$0

Latest News

Is CRA International’s New Bria-IMT Role Quietly Redefining Its Healthcare Moat and Pricing Power (CRAI)? Simply Wall St. · Jul 18, 2026 BriaCell Opens First Canadian Site For Phase 3 Metastatic Breast Cancer Study MT Newswires · Jul 16, 2026 BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer GlobeNewswire · Jul 16, 2026 BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™ GlobeNewswire · Jul 15, 2026 BriaCell Engages Consulting and Branding Firms to Support Potential Commercialization of Bria-IMT MT Newswires · Jul 7, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-8.0M$-12.0M$-24.0M$-24.0M$-29.0M
Investing Cash Flow$0$0$0$-1.0M$-8.0M
Financing Cash Flow$14.0M$-4.0M$0$0$0
Net Cash Flow$57.0M$-16.0M$-20.0M$-20.0M$10.0M
Free Cash Flow$-8.0M$-12.0M$-24.0M$-25.0M$-29.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.00
FCF Yield-448.52%
Quick Ratio7.07
Interest Coverage-1080.17
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AIMD $1.49 -3.87% -0.43 $10.97M 0.00%
ATXIAvenue Therapeutics, Inc. $0.26 -32.94% -0.49 $856691 0.00%
DRMA $1.10 -0.90% -0.15 $749713 0.00%
ELAB $0.92 +2.21% 0.00 $1.78M 0.00%
MLECMoolec Science S.A. $7.37 +2.43% -0.03 $5.35M 0.00%

About BriaCell Therapeutics Corp. Warrant

BriaCell Therapeutics Corp., a biotechnology company based in West Vancouver, Canada, is intensely focused on immuno-oncology, dedicated to engineering novel immunotherapies for cancer treatment. Its flagship compound, Bria-IMT, is a whole-cell cancer vaccine presently in Phase I/IIa clinical development, where it's being evaluated in conjunction with the investigational immunotherapy retifanlimab. The company's pipeline also includes Bria-OTS, a personalized, ready-to-use immunotherapy intended for advanced breast cancer, and BriaDx, a diagnostic tool for determining patient HLA types. BriaCell maintains a non-exclusive clinical trial collaboration with Incyte Corporation to explore the effects of combining various novel clinical candidates. Furthermore, a cooperative research and development agreement with the National Cancer Institute supports preclinical efforts to advance and test Bria-OTS cellular immunotherapy as a cancer therapy.

BriaCell Therapeutics Corp. Warrant is headquartered in CA.

BriaCell Therapeutics Corp. Warrant (BCTXZ) stock trades at $0.10 with a market capitalization of $188186. The stock is valued at a price-to-earnings (P/E) ratio of -0.30, price-to-book of 1.11, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.09 and $0.10, and currently trades at its 52-week high.

On profitability, BriaCell Therapeutics Corp. Warrant generates a return on equity (ROE) of -147.92%, return on capital employed of -136.31%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.briacell.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides